Complementary and alternative medicine use among newly diagnosed prostate cancer patients

Supportive Care in Cancer

Volumn 20, Issue 1, 2012, Pages 65-73

  McDermott, Cara L ^a   Blough, David K ^b   Fedorenko, Catherine R ^a   Arora, Neeraj K ^c   Zeliadt, Steven B ^a,d   Fairweather, Megan E ^a   Oakley Girvan, Ingrid ^e   Van Den Eeden, Stephen K ^f   Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Sound Health Care System   (United States)

^e CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^f DIVISION OF RESEARCH   (United States)

Author keywords

Alternative medicine; Complementary medicine; Patient satisfaction; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RELIGION; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

AGED; COMPLEMENTARY THERAPIES; DECISION MAKING; FOLLOW-UP STUDIES; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 83555163908     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1055-y     Document Type: Article

References (38)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z et al (eds.) (2010) Seer cancer statistics review, 1975-2007, National Cancer Institute. Available at: http://seer.cancer.gov/csr/ 1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed 17 Sept 2010
2. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64(6):1171-1176 (Pubitemid 39647061)
3. National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology, prostate cancer. Available at: http://www.nccn.org/professionals/ physician-gls/PDF/prostate.pdf. Accessed 15 Mar 2009
4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148(6):435-448 (Pubitemid 351665443)
5. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(6):2106-2131 (Pubitemid 46726449)
6. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR et al (1995) Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154(6):2144-2148
7. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Wennberg JE (1993) A structured literature review of treatment for localized prostate cancer. Prostate disease patient outcome research team. Arch Fam Med 2(5):487-493
8. Swarup AB, Barrett W, Jazieh AR (2006) The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol 29(5):468-473 (Pubitemid 44536028)
9. Evans M, Shaw A, Thompson EA, Falk S, Turton P, Thompson T, Sharp D (2007) Decisions to use complementary and alternative medicine (CAM) by male cancer patients: information-seeking roles and types of evidence used. BMC Complement Altern Med 7:25
10. Mansky PJ, Wallerstedt DB (2006) Complementary medicine in palliative care and cancer symptom management. Cancer J 12 (5):425-431 (Pubitemid 44564825)
11. National Center for Complementary and Alternative Medicine (2010) The use of complementary and alternative medicine in the united states. National Institutues of Public Health. Available at: http://nccam.nih.gov/news/camstats/ 2007/camsurvey-fs1.htm. Accessed 17 Sept 2010
12. Boon H, Brown JB, Gavin A, Westlake K (2003) Men with prostate cancer: making decisions about complementary/alternative medicine. Med Decis Mak 23(6):471-479 (Pubitemid 37448912)
13. Lippert MC, McClain R, Boyd JC, Theodorescu D (1999) Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86(12):2642-2648 (Pubitemid 30004668)
14. Fasching PA, Thiel F, Nicolaisen-Murmann K, Rauh C, Engel J, Lux MP, Beckmann MW, Bani MR (2007) Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer 15(11):1277-1284 (Pubitemid 47583442)
15. Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Platin N, Hummerston S, Scott JA, Panteli V, Gudmundsdottir G, Selvekerova S, Patiraki E, Kearney N (2005) Complementary and alternative medicine use in colorectal cancer patients in seven european countries. Complement Ther Med 13(4):251-257 (Pubitemid 43024870)
16. Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM, Rummans TA, Maurer MJ, Sloan JA, Geyer SM, Cerhan JR (2009) Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol 84(12):795-798
17. Zeliadt SB, Ramsey SD, Potosky AL, Arora NK, Oakley-Girvan I, Hamilton AS, Van Den Eeden SK, Penson DF (2008) Association of pre-existing symptoms with treatment decisions among newly diagnosed prostate cancer patients. The Patient 1(3):189-200
18. Ramsey SD, Zeliadt SB, Arora NK, Blough DK, Penson DF, Oakley-Girvan I, Hamilton AS, Van Den Eeden SK, Fedorenko CR, Potosky AL (2010) Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. J Urol 184(1):120-125
19. Rose A, Peters N, Shea JA, Armstrong K (2004) Development and testing of the health care system distrust scale. J Gen Intern Med 19(1):57-63 (Pubitemid 38221952)
20. Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA (2003) Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care 41(8):923-936
21. Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, Holland JC, Breitbart W (2003) The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer 97(11):2910-2918 (Pubitemid 36605162)
22. Mehta SS, Lubeck DP, Pasta DJ, Litwin MS (2003) Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CAPSURE. J Urol 170(5):1931-1933 (Pubitemid 37254963)
23. Arora NK, Weaver KE, Clayman ML, Oakley-Girvan I, Potosky AL (2009) Physicians' decision-making style and psychosocial outcomes among cancer survivors. Patient Educ Couns 77 (3):404-412
24. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG (2000) Development and validation of the expanded prostate cancer index composite (epic) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (6):899-905
25. National Cancer Institute (2008) Assessment of patients' experience of cancer care (APECC) study survey instrument. Available at: http://outcomes. cancer.gov/surveys/apecc/download.html. Accessed 17 Sept 2010
26. Steenland K (2006) Personal communication of baseline and first follow-up questionnaires
27. National Institutes of Health. National Center for Complementary and Alternative Medicine (2009) What is CAM? NCCAM, National Institutes of Health. Available at: http://nccam.nih.gov/health/whatiscam/overview.htm. Accessed 2 Jul 2010
28. D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ (2006) Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 176(6 Pt 2):S11-S15 (Pubitemid 44648140)
29. Tippens K, Marsman K, Zwickey H (2009) Is prayer CAM? J Altern Complement Med 15(4):435-438
30. Brown CM, Barner JC, Richards KM, Bohman TM (2007) Patterns of complementary and alternative medicine use in African Americans. J Altern Complement Med 13(7):751-758 (Pubitemid 47585339)
31. Lee MM, Chang JS, Jacobs B, Wrensch MR (2002) Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 92(10):1606-1609
32. Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2(3):212-216 (Pubitemid 37127925)
33. Jones RA, Taylor AG, Bourguignon C, Steeves R, Fraser G, Lippert M, Theodorescu D, Mathews H, Kilbridge KL (2007) Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. Oncol Nurs Forum 34(2):359-364
34. Bausell RB, Lee WL, Berman BM (2001) Demographic and health-related correlates to visits to complementary and alternative medical providers. Med Care 39(2):190-196 (Pubitemid 33603628)
35. Carpenter CL, Ganz PA, Bernstein L (2009) Complementary and alternative therapies among very long-term breast cancer survivors. Breast Cancer Res Treat 116(2):387-396
36. Diefenbach MA, Hamrick N, Uzzo R, Pollack A, Horwitz E, Greenberg R, Engstrom PF (2003) Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol 170 (1):166-169 (Pubitemid 36734442)
37. Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, Livingston ML, Ruiterman J, Ampela R, Kaw OC, Blanchard C (2005) Patient-physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23(4):35-60 (Pubitemid 43856720)
38. Wilkinson S, Farrelly S, Low J, Chakraborty A, Williams R (2008) The use of complementary therapy by men with prostate cancer in the UK. Eur J Cancer Care (Engl) 17(5):492-499